Aethlon Medical, Inc. (AEMD)
NASDAQ: AEMD · Real-Time Price · USD
3.700
-0.330 (-8.19%)
At close: Dec 5, 2025, 4:00 PM EST
3.810
+0.110 (2.97%)
After-hours: Dec 5, 2025, 7:55 PM EST
Aethlon Medical Employees
Aethlon Medical had 9 employees as of March 31, 2025. The number of employees decreased by 5 or -35.71% compared to the previous year.
Employees
9
Change (1Y)
-5
Growth (1Y)
-35.71%
Revenue / Employee
n/a
Profits / Employee
-$1,250,959
Market Cap
2.82M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
AEMD News
- 14 hours ago - Aethlon Medical Announces Pricing of a Private Placement and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $3.3 Million - PRNewsWire
- 3 days ago - Aethlon Medical Announces Publication of Preclinical Data Showing That the GNA Affinity Resin in the Hemopurifier® Binds to Extracellular Vesicles in Long COVID patient samples and Decreases Inflammatory microRNAs - PRNewsWire
- 23 days ago - Aethlon Medical, Inc. (AEMD) Q2 2026 Earnings Call Transcript - Seeking Alpha
- 23 days ago - Aethlon Medical Announces Fiscal Q2 2025 Financial Results and Corporate Update - PRNewsWire
- 4 weeks ago - Aethlon Medical to Release Fiscal Second Quarter Financial Results and Host Conference Call on November 12, 2025 - PRNewsWire
- 2 months ago - Aethlon Medical's Hemopurifier® shows Changes in Extracellular Vesicles, Extracellular MicroRNAs, and T Cell Numbers in Australian Oncology Clinical Trial - PRNewsWire
- 3 months ago - Aethlon Medical Announces Pricing of $4.5 Million Public Offering - PRNewsWire
- 3 months ago - Aethlon Medical Announces Issuance of Hemopurifier® Patents for the Treatment of Long COVID and COVID-19-associated Coagulopathy (CAC) - PRNewsWire